EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023
W.J. Fokkens, A-S Viskens, V. Backer, Diego M. Conti, E De Corso, Philippe Gevaert, G K Scadding, M. Wagemann, Manuel Bernal‐Sprekelsen, Adam Chaker, Enrico Heffler, Jianjun Han, E Van Staeyen, C Hopkins, J Mullol, Aaron W. Peters, Sietze Reitsma, Brent A. Senior, Peter W. Hellings
Abstract
Severe chronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating disease with a significant impact on the quality of life (QoL). It is typically characterized by a type 2 inflammatory reaction and by comorbidities such as asthma, allergies and NSAID-Exacerbated Respiratory Disease (N-ERD). Here, the European Forum for Research and Education in Allergy and Airway diseases discusses practical guidelines for patients on biologic treatment. Criteria for the selection of patients who would benefit from biologics were updated. Guidelines are proposed concerning the monitoring of the drug effects that provide recognition of responders to the therapy and, subsequently, the decision about continuation, switching or discontinuation of a biologic. Furthermore, gaps in the current knowledge and unmet needs were discussed.